SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community actively champions the "OG meme" narrative of Rage Comics, viewing it as the foundational "meme reset." This dedicated base is passionately building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and widespread recognition as they aim to lead the next major meme coin cycle.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Federal reclassification of cannabis and the elimination of the 280E tax barrier are driving significant attention to Weedcoin, as the community positions it as a key beneficiary of these policy changes on Solana. Enthusiasts are rallying around its 

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF is generating significant buzz as investors grapple with its perceived disconnection from the underlying asset. Intense community discussions center on the impact of distributions and the inherent decay of this leveraged product, leading to a polarized debate over its immediate trajectory and risk profile.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is seeing significant community discussion driven by the departure of its CFO, which has sparked diverse speculation about a potential acquisition, alongside a new expanded access agreement for its rare disease treatment, MIPLYFFA, to broaden global reach. Simultaneously, investors are closely watching the ongoing legal proceedings with Commave, with varying interpretations of recent court developments influencing sentiment around the future of its KP1077 asset.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high December and fourth-quarter 2025 vehicle deliveries, meeting the high end of its guidance and nearing one million cumulative vehicles overall. This strong performance, coupled with China's extended EV purchase tax benefits favoring battery-swapping models, has ignited community discussions about potential Q4 profitability and a bright 2026 outlook for the multi-brand EV maker. Many investors are optimistic, comparing NIO's sales favorably against peers and anticipating significant upside despite recent price volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending significantly following the FDA's Complete Response Letter to competitor Corcept Therapeutics for its Cushing's syndrome treatment. This outcome is widely viewed by the community and analysts as a "massive tailwind" for Xeris's Recorlev, strengthening its market position in a growing multi-billion dollar sector. Investors are actively discussing this enhanced competitive moat and the promising future of its XP-8121 pipeline.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending amid recent regulatory approvals for a key acquisition and an analyst firm initiating coverage with an "Overweight" rating. While some investors voice frustration over past delays in commercial revenue and management communication, a significant portion of the community maintains strong conviction in the long-term potential of its specialized isotope technology for critical sectors including advanced energy, medical applications, and next-generation computing. The conversation highlights a divide between those concerned about execution timelines and those focused on strategic asset accumulation and the company's unique market position.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending after definitively agreeing to sell Bressner Technology for $22.4M, a strategic move the community views as a profitable pivot to focus on high-growth AI and edge computing. This substantial cash infusion and sharpened corporate focus are fueling strong anticipation for impending large military contracts, particularly a potential $200M situational awareness system. Investors are actively discussing the company's low float and undervalued status, anticipating significant upside as the AI and defense narrative gains wider recognition.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending amid intense community debate surrounding mixed interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, where positive mucus plug reduction signals are being weighed against limited lung function improvement. Concurrently, investors are closely following a high-stakes trade secret lawsuit against AbbVie, which many believe could lead to a significant settlement or buyout, fueling conversations about the stock's perceived undervaluation and potential for a substantial short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 88.6% in December

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totaling 3,455,246 shares, a...

Penny Stocks To Watch Now - December 2nd

Beyond Meat, Bitfarms, Fitell, Eventbrite, and Jasper Therapeutics are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small...

Jasper Stock Jumps After Promising New Asthma Study Results

Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.read more...

JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. (Jasper or the Company) (NASDAQ: JSPR) and reminds investors of the...

Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of...

JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR

JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper...

JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit

JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities...

JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors there is a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between...

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Jasper Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. (Jasper or the Company) (NASDAQ: JSPR). Faruqi & Faruqi is a leading...

JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit

JSPR Deadline: JSPR Investors with Losses in Excess of $100K Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit JSPR Deadline: JSPR Investors with Losses in Excess of $100K...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Current Price	$1.83
Prev Close	$1.79
Open	$1.78
Dividend Yield	0.00%
50-Day Moving Average	$1.88
Beta	1.22
Avg. Volume	418,584.84
PE Ratio	-0.31

52-Week High	$22.52
52-Week Low	$1.39
Market Capitalization	$50.09M
EPS (Annual)	-$4.89
Price to Book	4.43
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

JSPR
Jasper Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JSPR News

JSPRJasper Therapeutics Inc